HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mosquito Repellent Promotion Tumbles On Undisclosed Paid Social Media Plugs By US Olympic Gymnasts

This article was originally published in The Rose Sheet

Executive Summary

FTC proposes settlements with marketing and public relations firm Creaxion and Inside Publications over regulatory violations in advertising for Fit Organic Mosquito Repellent including failing to disclose US Olympic gymnasts as paid social medial endorsers and misrepresenting that paid commercial ads are opinions from an independent or objective publishers or sources.

You may also be interested in...



FTC Takes First Enforcement Action Against Social Media Influencers

A pair of social media influencers in the online gaming space are the first to be targeted by an FTC complaint for failures to properly disclose material connections to endorsed services. The commission has issued warning letters to 21 others for similar compliance issues following an "educational" letter campaign in April.

Health & Wellness Industry News Roundup: Week Of Aug. 1

Kratom seized again; FTC warns on Zika claims; EntereoMed passes 2 of 3 UK gut health claim checks; Bevolution adds Dr. Smoothie to lineup; physicians committee recommends prebiotics; and more news in brief.

Fraudulent Zika Claims Are CDER's Latest Extermination Target

CDER is on the lookout for companies seeking to capitalize off the Zika health crisis with fraudulent claims about their products’ ability to treat or prevent the disease, says Brad Price, acting director of the Division of Nonprescription Drugs and Health Fraud, Office of Compliance.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS122492

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel